Your AI-Trained Oncology Knowledge Connection!
Charles M. Perou, PhD, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of Genetics, and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, discusses the biomarker assay results as described in the ASCO breast cancer guideline.
Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the adjuvant use of ipilimumab (Yervoy) in patients with melanoma.
Deirdre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses emerging agents for the treatment of patients with gastric cancer.
S. Vincent Rajkumar, MD, professor of Medicine at Mayo Clinic, discusses the significance of the phase III SWOG S0777 study, which looked at bortezomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with previously untreated multiple myeloma.
Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and director of the Kimmel Cancer Center Network, discusses the current perspectives on screening for prostate cancer.
Jorge E. Cortes, MD, deputy department chair, professor of Medicine and Internist, chair, AML Sections, D. B. Lane Cancer Research Distinguished Professor for Leukemia Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action for BP-100.01.
Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.
Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses marginal zone lymphoma.
Kimberly J. Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses nomograms as a tool to determine the risk of recurrence for patients with ductal carcinoma in situ (DCIS).
Andrew R. Branagan, MD, postdoctoral associate in Medicine (Hematology), Yale Cancer Center, discusses the significance of a vaccine developed to better protect patients with multiple myeloma from getting the flu.
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses immunotherapy agents for the treatment of patients with bladder cancer.
Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical approach for patients with HER2-positive breast cancer.
David Sher, MD, radiation oncologist, UT Southwestern Medical Center, provides an update on and the basis for ASTRO's Multidisciplinary Head and Neck Cancer Guideline.
Heather Wakelee, MD associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses treating EGFR-mutant patients with lung cancer who are resistant to EGFR tyrosine kinase inhibitors (TKIs).
Michael A. Thompson, MD, PhD, oncology/hematology, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses easy steps for oncologists to start using social media.
Stephen Stilgenbauer, MD, associate professor, Department of Haematology, Oncology, Rheumatology and Infectious Diseases, University of Ulm, Germany, discusses the clinical activity seen with venetoclax in patients with chronic lymphocytic leukemia, according to results of the open-label, single-arm, multicenter M13-982 study.
Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer.
Mario Sznol, MD, professor of Medicine, Yale Cancer Center, shares how to discuss immunotherapy as a treatment option for patients with renal cell carcinoma (RCC).
E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses factors in selecting abiraterone versus enzalutamide for the treatment of patients with castration-resistant prostate cancer.
William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumumab as a treatment for patients with soft tissue sarcoma.
Katherine Krajewski, MD, associate director, physician, Cancer Imaging Program Fellowship, Dana-Farber Cancer Institute, assistant professor of Radiology, Harvard Medical School, discusses the range of responses seen in patients with renal cell carcinoma (RCC) who have received PD-1 agents as treatment.
Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).
Peter Martin, MD, associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, predicts future treatment approaches in the field of mantle cell lymphoma (MCL).
James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.
David C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.
Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.
Elias Obeid, MD, MPH, assistant professor, Department of Clinical Genetics, Fox Chase Cancer Center, discusses a retrospective analysis that investigated androgen receptor expression in patients with triple-negative breast cancer. (TNBC).
Zachary C. Landman, MD, clinical fellow in Orthopedic Surgery, Department of Orthopedic Surgery, Massachusetts General Hospital, discusses the process of delivering value-based care to patients with cancer.
Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, deputy director, Penn State Hershey Cancer Institute, discusses how the FDA approval of nivolumab (Opdivo) has impacted the treatment paradigm of non–small cell lung cancer (NSCLC).
Tara C. Mitchell, MD, assistant professor of Medicine at the Hospital of the University of Pennsylvania, Perelman School of Medicine, discusses atypical responses with immunotherapies in melanoma.
